Feature

Beta Thalassemia: Pricey Gene Therapy Hits The Mark


 

Back on Long Island, a Sense of Relief

Several months after his treatment, Yusuf is doing well. His hemoglobin levels are increasing, and his bone marrow has grown back, his mother said. He’s being home-schooled for the time being because he still faces a risk of infection. (Ms. Ahmed, a stay-at-home mom, has worked a teacher and mosque volunteer. Her husband runs a consumer electronics business.)

As Yusuf gets better, his parents hope they’ll soon be able to take a long trip back home to Pakistan to see relatives. They’ll be able to share their son with family along with something else: a sense of relief.

Dr. Al-Samkari discloses consulting for Agios. Dr. Thompson discloses research for Beam, Bluebird Bio, Editas, Novartis, and Novo Nordisk and consulting for Beam, Bluebird Bio, Editas, Roche, and Vertex.

Pages

Recommended Reading

Sickle Cell Gene Therapy ‘Truly Transformative’
MDedge Hematology and Oncology
Sickle Cell: Good Outcomes for Haploidentical Transplants
MDedge Hematology and Oncology
SCD mortality rates improved for Black patients in 2010s
MDedge Hematology and Oncology
Sickle Cell CRISPR Gene Therapy May Offer Patients ‘Functional Cure’
MDedge Hematology and Oncology
CRISPR-Based Gene Therapy Earns Beta Thalassemia Approval
MDedge Hematology and Oncology
Democratic Lawmakers Press Pfizer on Chemotherapy Drug Shortages
MDedge Hematology and Oncology
EU Backs First Oral Monotherapy for Adults With PNH
MDedge Hematology and Oncology
FDA OKs Danicopan Add-On for Extravascular Hemolysis in Adults With PNH
MDedge Hematology and Oncology
FDA Approves Second Gene Therapy for Hemophilia B
MDedge Hematology and Oncology
SCD: Delaying Transition to Adult Care Poses Risks
MDedge Hematology and Oncology